| Literature DB >> 29768996 |
Jan Korabecny1, Katarina Spilovska1, Eva Mezeiova1, Ondrej Benek1, Radomir Juza1, Daniel Kaping1, Ondrej Soukup1.
Abstract
Alzheimer's Disease (AD) is a multifactorial progressive neurodegenerative disorder characterized by memory loss, disorientation, and gradual deterioration of intellectual capacity. Its etiology has not been elucidated yet. To date, only one therapeutic approach has been approved for the treatment of AD. The pharmacotherapy of AD has relied on noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist - memantine, and acetylcholinesterase (AChE) inhibitors (AChEIs) - tacrine, donepezil, rivastigmine and galantamine. Donepezil was able to ameliorate the symptoms related to AD mainly via AChE, but also through reduction of β-amyloid burden. This review presents the overview of donepezilrelated compounds as potential anti-AD drugs developed on the basis of cholinergic hypothesis to act as solely AChE and butyrylcholinesterase (BChE) inhibitors. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.Entities:
Keywords: Alzheimer’s disease; NMDA; acetylcholinesterase; butyrylcholinesterase; donepezil; inhibitor; treatment.
Mesh：
Substances：
Year: 2019 PMID： 29768996 DOI： 10.2174/0929867325666180517094023
Source DB: PubMed Journal: Curr Med Chem ISSN： 0929-8673 Impact factor: 4.530